Cross-posted from the Nature News Blog
A leading candidate for a sorely needed new vaccine against tuberculosis (TB) has failed to protect children against the disease in a major clinical trial.
Published today in The Lancet, the results of the trial of the MVA85A vaccine show that it seems to have “no significant efficacy” against either TB or infection with Mycobacterium tuberculosis.
The results are a major blow to the TB research community, as MVA85A had seemed highly promising as a solution to the problem of the patchy efficacy of the ‘BCG’ vaccine used worldwide against the disease.
Click here to continue reading.
Recent comments
Real-time tissue analysis could guide brain tumor surgery
Bundled RNA balls silence brain cancer gene expression
Ebola outbreak in West Africa lends urgency to recently-funded research